1. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy
- Author
-
Maria Laura Sorgi, Marco Canzoni, Christina von Hunolstein, Roberto Ieraci, Milica Markovic, Bruno Laganà, Francesca Romana Spinelli, Raffaele D'Amelio, Sabrina Mariotti, Luisa Ralli, Raffaela Teloni, Roberto Nisini, Antonietta Pinto, Simonetta Salemi, Andrea Picchianti Diamanti, Mayla Sgrulletti, Roberta Di Rosa, Claudia Ferlito, Guido Valesini, Giorgia Meneguzzi, S. Caporuscio, and Gerardo Salerno
- Subjects
Male ,Serotype ,13-valent pneumococcal conjugate vaccine ,Immunology ,Pneumococcal Infections ,Arthritis, Rheumatoid ,Pneumococcal Vaccines ,Immunocompromised Host ,03 medical and health sciences ,0302 clinical medicine ,Conjugate vaccine ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Rheumatoid arthritis ,Aged ,030203 arthritis & rheumatology ,biology ,business.industry ,Corynebacterium diphtheriae ,Diphtheria ,Immunogenicity ,Polysaccharides, Bacterial ,Vaccination ,Middle Aged ,medicine.disease ,Antibodies, Bacterial ,Immunity, Humoral ,Immunosuppressive therapy ,Italy ,Antibody persistence ,Immunoglobulin G ,biology.protein ,Female ,Tumor necrosis factor alpha ,Antibody ,business ,Immunosuppressive Agents - Abstract
Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.
- Published
- 2018